Wang, W., Erbe, A. K., Gallenberger, M., Kim, K., Carmichael, L., Hess, D., . . . Sondel, P. M. (2016). Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2. Cancer Immunol Immunother.
シカゴスタイル引用形Wang, Wei, et al. "Killer Immunoglobulin-like Receptor (KIR) and KIR–ligand Genotype Do Not Correlate With Clinical Outcome of Renal Cell Carcinoma Patients Receiving High-dose IL2." Cancer Immunol Immunother 2016.
MLA引用形式Wang, Wei, et al. "Killer Immunoglobulin-like Receptor (KIR) and KIR–ligand Genotype Do Not Correlate With Clinical Outcome of Renal Cell Carcinoma Patients Receiving High-dose IL2." Cancer Immunol Immunother 2016.